Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cancerscreen

CANCERSCREEN SIGNED

Screening for cancer in the post-genomic era: diagnostic innovation and biomedicalisation in comparative perspective

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CANCERSCREEN project word cloud

Explore the words cloud of the CANCERSCREEN project. It provides you a very rough idea of what is the project "CANCERSCREEN" about.

risks    linking    interactions    opinion    diagnostic    dimensions    reconfiguring    innovative    integrative    molecular    integration    technologies    transnational    age    accompanied    unprecedented    socio    regulatory    decade    public    health    transition    revolution    technological    harms    redrawing    patenting    insights    gene    categories    data    surrounding    biomedicine    model    trajectories    private    anecdote    tests    cancer    scholarship    innovation    1996    regulation    human    disease    first    investments    detection    domain    genome    steer    empirical    quantitative    economy    generation    genomic    day    screening    usa    continue    actors    platform    biomedicalisation    diagnostics    expert    policy    qualitative    deliberation    theory    monopolies    shaping    fuel    boundaries    political    freight    inter    combining    dynamics    paucity    decision    map    alia    conceptual    industry    sickness    expectations    regime    examine    scientometric    literature   

Project "CANCERSCREEN" data sheet

The following table provides information about the project.

Coordinator		 THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Total cost 1˙347˙992 €
 EC max contribution 1˙347˙992 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 1˙047˙674.00
2    THE UNIVERSITY OF SUSSEX UK (BRIGHTON) participant 300˙317.00

Map

 Project objective

Cancer screening and the diagnostics industry: a comparative analysis of the political economy of diagnostic innovation A decade after the Human Genome Project, major public and private investments continue to fuel expectations of a genomic revolution in biomedicine. The freight of expectations surrounding the new “age of diagnostics” is accompanied by much uncertainty about how public policy should steer diagnostic innovation, with much debate about inter alia the harms of creating diagnostic monopolies through gene patenting, and the risks of under- or over-regulation. However, due to the paucity of research on diagnostic innovation, policy deliberation is driven more by anecdote and expert opinion than empirical evidence. With a specific focus on screening/early detection of cancer, this project will map industry dynamics, technological trajectories and regulatory developments in Europe and the USA from 1996 to the present day. Combining quantitative and qualitative methods, the project’s innovative dimensions include a new conceptual model of socio-technical transition in the diagnostics sector, and the first integrative analysis linking scientometric data on the interactions between public and private actors in the diagnostic research domain with comparative transnational analysis of regulatory decision-making. Through a novel integration of conceptual insights from the literature on biomedicalisation and scholarship on socio-technical regime change, this project aims to advance both fields of research by applying a new multi-scale, multi-level model of socio-technical transition. The project will provide unprecedented insight into the factors shaping the development of a new generation of molecular diagnostic tests, and examine how these technologies are reconfiguring disease categories and redrawing the boundaries between health and sickness. We will establish a platform of theory and methods for a broader programme of work on diagnostic innovation.

 Publications

year authors and title journal last update
List of publications.
2019 Kelly Holloway, Fiona A Miller, Alberto Gutierrez, Stuart Hogarth
Dangerous diagnostics? Regulatory reform in the genomic era
published pages: l640, ISSN: 0959-8138, DOI: 10.1136/bmj.l640 		BMJ 2020-01-30
2019 Kelly Holloway, Fiona A. Miller, François Rousseau, Alberto Gutierrez, Stuart Hogarth
Health Canada needs to act on laboratory-developed diagnostics
published pages: E1067-E1069, ISSN: 0820-3946, DOI: 10.1503/cmaj.190550 		Canadian Medical Association Journal 191/39 2020-01-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANCERSCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANCERSCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

In Motion (2018)

Investigation and Monitoring of Time-varying Environments on Macro and Nano Scales

Read More  

MEMO (2020)

The Memory of Solitons

Read More  

CONT-END (2018)

Attempts to Control the End of Life in People with Dementia: Two-level Approach to Examine Controversies

Read More